The positive effects of FKBP51 antagonism on glucose tolerance reported here suggest the opportunity to develop FKBP51 antagonists for the clinic, especially for the treatment of stress-related T2D. This evidence concerns the gene FKBP4 and type 2 diabetes mellitus.